Skip to main content
italianoIT
European Commission logo print header

Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer

Obiettivo

Breast cancer represents a leading cause of cancer death in women and a major socio-economic issue. With currently available methods, early diagnosis frequently fails. Moreover, beyond mere detection, there is an ever-increasing need for improved non-invasive characterisation of cancer. Targeted therapies require an in-depth analysis of cancer to select and guide appropriate treatment. Both, PET and MRI can provide molecular and functional information that may be of pivotal importance for tailoring therapy. However, current whole-body PET/MRI systems lack the necessary sensitivity and resolution for this task. HYPMED addresses this by engineering an innovative imaging tool. HYPMED will integrate an innovative fully-digital MRI-transparent PET-detector into a novel multi-channel PET-transparent MRI surface coil. The PET-RF insert will allow unprecedented imaging of breast cancer with high-resolution/ultra-high sensitivity PET, combined with high-level structural and functional MRI, and allow minimal-invasive MR- and PET-guided targeted biopsy. Moreover with such PET-RF inserts, every regular clinical MR-system can, upon demand, be turned into a hybrid system. We will evaluate the impact of this technology on breast cancer diagnosis, prediction, and monitoring/assessment of treatment response by a carefully designed clinical study that employs established and novel PET tracers in 250 patients. Imaging data will be correlated with established and novel molecular biomarkers; results will be compared to those obtained from whole-body PET/MRI and PET/CT. A multidisciplinary consortium of clinical scientists, 3 SMEs and an industry partner will pave the way for commercialization of HYPMED products for advanced clinical decision making in cancer patients. Once HYPMED is successful, we will expand this approach to other applications such as prostate cancer or cardiac hybrid imaging, and thus introduce a paradigm shift in the field of PET/MR hybrid imaging as a whole.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-PHC-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-PHC-2015-two-stage

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG
Contribution nette de l'UE
€ 394 637,50
Indirizzo
AM GESTADE 1
1010 Wien
Austria

Mostra sulla mappa
Regione
Ostösterreich Wien Wien
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 394 637,50

Partecipanti (9)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 1 Febbraio 2024

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/667211/it

European Union, 2024